title: Who should receive biologic therapy for IBD?: The rationale for the application of a personalized approach.
abstract: The therapeutic approach in inflammatory bowel disease has evolved to target end-organ inflammation to heal intestinal mucosa and avoid structural damage. Objective therapeutic monitoring is required to achieve this goal. Earlier intervention with biologic therapy has been shown, indirectly, to be associated with higher clinical response and remission rates. A personalized approach to risk stratification with consideration of key clinical factors and inflammatory biomarker concentrations is recommended when deciding whether or not to start a patient on biologic therapy.
authors.affiliation: Department of Medicine, University of Saskatchewan, 108 Hospital Drive, Saskatoon, Saskatchewan S7N0W8, Canada. Electronic address: j.jones@usask.ca.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Jones
authors.affiliation: Department of Medicine, School of Public Health, University of Saskatchewan, 104 Clinic Place, Saskatoon, Saskatchewan S7N 5E5, Canada.
authors.forename: Juan Nicolás
authors.initials: JN
authors.lastname: Peña-Sánchez
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D010347:Patient Care Planning; D018579:Patient Selection; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D014409:Tumor Necrosis Factor-alpha
keywords: Biologic therapy; Crohn disease; IBD; Inflammatory bowel disease; Ulcerative colitis